1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Drugs In Development, 2022, provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Radiation Toxicity (also known as radiation sickness) is an acute illness caused by irradiation of the entire body by a high dose of penetrating radiation in a very short period of time (usually a matter of minutes). The major cause of this syndrome is depletion of immature parenchymal stem cells in specific tissues. Symptoms include bleeding from the nose, mouth, gums, and rectum, bloody stool, bruising, confusion, dehydration, diarrhea, fainting and fatigue.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 12, 8, 1, 51, 6 and 2 respectively. Similarly, the Universities portfolio in Preclinical, Discovery and Unknown stages comprises 6, 1 and 1 molecules, respectively.
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Overview
- Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Companies Involved in Therapeutics Development
- Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Drug Profiles
- Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects
- Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products
- Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Product Development Milestones
- Featured News & Press Releases
- Oct 19, 2022: Enzychem Lifesciences announces poster presentation of EC-18 at the Radiation Research Society 2022 annual meeting
- Oct 19, 2022: Enzychem Lifesciences announces poster presentation of EC-18 at the Radiation Research Society 2022 annual meeting
- Jul 21, 2022: Eckert & Ziegler Affiliate receives further NIAID funding for clinical development
- Apr 26, 2022: New studies published comparing BIO 300 to Neulasta for acute radiation syndrome
- Mar 24, 2022: Tanner Pharma increases Europe-based inventory of Leukine to expand availability and enhance response to potential radiation exposure due to the ongoing Conflict in Ukraine
- Dec 01, 2021: Statera Biopharma announces FDA lifts clinical hold on entolimod
- Nov 18, 2021: Enveric Biosciences announces positive preclinical data for EV102 Radiodermatitis Drug Candidate
- Sep 22, 2021: Humanetics announces results from phase 1 trial of BIO 300 oral powder
- Jul 20, 2021: Neuropathix announces publication of PCT patent application for the treatment of radiation dermatitis and other skin disorders
- Jun 08, 2021: Affiliate receives additional NIAID funding to advance pharmaceutical development
- Feb 18, 2021: Partner Therapeutics announces publication of two studies demonstrating Leukine improves survival in Acute Radiation Syndrome (ARS)
- Feb 08, 2021: Enzychem Lifesciences announces poster presentation at AACR Virtual Annual Meeting 2021
- Jan 26, 2021: Enzychem Lifesciences receives NASA grant funding to evaluate EC-18 as a protective agent for radiation and pathogen-induced tissue damage and inflammation in space
- Oct 20, 2020: Humanetics presents at the Annual Radiation Research Society meeting
- Oct 15, 2020: Meabco's drug candidate efficiently mitigates radiation-induced gastrointestinal syndrome in mice
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Target, 2022 (Contd..1)
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, 2022
- Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products, 2022
List of Figures
- Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 9 Meters Biopharma Inc
- Advanced Innovative Partners Inc
- Advenchen Laboratories LLC
- Aileron Therapeutics Inc
- Allander Biotechnologies LLC
- Amryt Pharma Plc
- Aqualung Therapeutics Corp
- BCN Biosciences LLC
- BioCurity Pharmaceuticals Inc
- BioIncept LLC
- Bolder Biotechnology Inc
- Cellphire Inc
- Ceramedix Holding LLC
- Ceramide Therapeutics LLC
- Chrysalis BioTherapeutics Inc
- Clevexel Pharma SA
- Connext Co Ltd
- Consegna Pharma Inc
- Creative Medical Technology Holdings Inc
- Devonian Health Group Inc
- Enveric Biosciences Inc
- Enzychem Lifesciences Corp
- EpicentRx Inc
- Exponential Biotherapies Inc
- Extend Biosciences Inc
- Fibroplate Inc
- Foresee Pharmaceuticals Co Ltd
- Genexine Inc
- Genome Protection Inc
- GNI Group Ltd
- Humanetics Corp
- iNtRON Biotechnology Inc
- KBP Biosciences Co Ltd
- Lutris Pharma
- Luxena Pharmaceuticals Inc
- Matrix Biomed Inc
- Meabco AS
- Medesis Pharma SA
- Neumedicines Inc
- Neuropathix Inc
- New Amsterdam Sciences Inc
- Novartis AG
- Noveome Biotherapeutics Inc
- Onconova Therapeutics Inc
- Original BioMedicals Co Ltd
- Oxacell AG
- P2D Inc
- Partner Therapeutics Inc
- Perpetuum BV
- PharmaIN Corp
- Phoenicia Biosciences Inc
- Pluristem Therapeutics Inc
- Regeneus Ltd
- RepoCeuticals ApS
- RxBio Inc
- Soligenix Inc
- Statera Biopharma Inc
- Sunny Pharmtech Inc
- Synedgen Inc
- TheraSource LLC
- Tonix Pharmaceuticals Holding Corp
- Valenta Pharm
- VasoDynamics Ltd
- Vera Salus Ricerca Srl
- Worphmed Srl
- Xequel Bio Inc
